ChromaTan has announced the award of an NIH grant in the amount of $2 million.
ChromaTan, a bioprocessing and biotools advanced biomanufacturing technology platform development company, is excited to announce the award of NIH IIB grant of $2M from the National Institute of General Medical Sciences, for the development and integration of ChromaTan’s novel BioRMB™ single-use, column-free, steady-state continuous counter-current elution technology for manufacturing AAVs. This project further highlights ChromaTan’s commitment to improving biologics manufacturing, while reducing manufacturing costs and optimizing the environmental footprint of biopharmaceuticals through process intensification.
The project aims to develop AAV purification process trains for at least 2 AAV serotypes sourced from Chromatan’s commercial partners for both capture and polishing (empty/full separation) as well as scale the BioRMB™ platform to both pilot and large-scale cGMP production.
"The BioRMB™ platform is a next generation bioprocessing technology that will lead to intensified and integrated continuous biomanufacturing. The approach is very powerful for multiple reasons such as improvements in manufacturability, process economics, improved recovery and product quality. This grant empowers us to take that idea a step further – by integrating these hyper-efficient next-generation platforms, we will have the potential to transform gene therapy manufacturing as we know it," says Oleg Shinkazh, Chief Technical officer at Chromatan.
This project is being developed with an award from the National Institute for General Medical Sciences (NIGMS) a constituent Institute of the National Institutes of Health (NIH – Grant number R44GM154572)
